Article
Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.
The Journal of pharmacology and experimental therapeutics - 1 Mar 1991
Jonkers R E, Koopmans R P, Portier E J, van Boxtel C J
Abstract excerpt
The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs. We investigated if the latter also applies to the beta-2 adrenoceptor...
Topics
- Administration, Oral
- Adult
- Debrisoquin
- Drug Interactions
- Female
- Humans
- Male
- Metoprolol
- Phenotype
- Receptors, Adrenergic, beta
- Stereoisomerism